Interest of the Tool: Evaluation of Specific Care in an Ecological Environment for Patients Suffering From Schizophrenia-like Disorders
NCT ID: NCT05349513
Last Updated: 2026-01-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
56 participants
INTERVENTIONAL
2022-02-23
2026-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Indeed, evaluation in an ecological environment would make it possible to be as close as possible to the concerns of theses patients, which could improve the care of this population, by making it possible to set with the patient objectives anchored in their daily life.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Influence of Environmental Factors and Schizophrenia
NCT03296384
Insight in Persons Presenting Schizophrenia or Related Troubles During Hospitalization in Psychiatry
NCT01611337
Study of the Impact on the Therapeutic Alliance of a Short Initial Psychoeducation Programme in Patients With Early Schizophrenia
NCT04867681
Neuropsychological Assessment of Remediation for Cognitive Impairments in Schizophrenia
NCT04608032
Synergy Between Physical Activity and Outdoor Green Environments to Reduce the Intensity of Negative Symptoms in Schizophrenia.
NCT07058389
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study includes the following visits :
* V0: Inclusion visit (Day 0) with the administration of standard of care questionnaires;
* V1: visit at patient's home (Day 0 +7 to 14 days) with the administration of the experimental ESSME questionnaire;
* V2: follow-up visit at 6 months (M6) with the administration of the same standard of care questionnaires than at the inclusion visit;
* V3: visit at patient's home (M6 + 7 to 14 days) with the administration of the experimental ESSME questionnaire.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
interventionnal arm
Administration of the experimental questionnaire ESSME in patient's environment.
ESSME questionnaire
The experimental ecological questionnaire ESSME is administered 7 to 14 days after the inclusion visit and 7 to 14 days after the 6 months follow-up visit to the patient at their home.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ESSME questionnaire
The experimental ecological questionnaire ESSME is administered 7 to 14 days after the inclusion visit and 7 to 14 days after the 6 months follow-up visit to the patient at their home.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* diagnosis of schizophrenia or schizoaffective disorder according to the Diagnostic and Statistical Manual of Mental Disorders version number 5 (DSM-V) criteria;
* patient receiving care in a Center for Rehabilitation and Intersectoral Therapeutic Activities (CREATIV);
* person who consented to the study;
* affiliate or beneficiary of a social security scheme.
Exclusion Criteria
* pregnant or breastfeeding women;
* person unable or unwilling to receive a home visit;
* person not consenting to the study;
* presence of a diagnosis of an associated neurodevelopmental disorder;
* presence of a diagnosis of dementia or associated neurodegenerative process;
* person with a level of French language insufficient to understand the items.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Henri Laborit
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier Henri Laborit
Poitiers, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-A00080-43
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.